EBITDA: Income before interest, taxes, depreciation and amortization.
Acurx Pharmaceuticals, Inc. (ACXP) had EBITDA of $-1.64M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-1.58M |
|
-- |
|
-- |
|
$1.64M |
|
$-1.64M |
|
$0.07M |
|
$-1.58M |
|
$-1.58M |
|
$-1.58M |
|
$-1.58M |
|
$-1.58M |
|
$-1.58M |
|
$-1.64M |
|
|
EBITDA |
$-1.64M |
1.50M |
|
1.50M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$7.69M |
|
-- |
|
-- |
|
$7.69M |
|
$2.42M |
|
-- |
|
-- |
|
$2.42M |
|
$5.27M |
|
$5.27M |
|
$5.27M |
|
2.35M |
|
| Cash Flow Statement Financials | |
$-6.79M |
|
-- |
|
$10.64M |
|
$3.71M |
|
$7.56M |
|
$3.85M |
|
$1.57M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.18 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.79M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-29.96% |
|
-29.96% |
|
-20.52% |
|
-29.96% |
|
$2.24 |
|
$-4.53 |
|
$-4.53 |
|